SYMQY (SymBio Pharmaceuticals) Total Liabilities: $16.65 Mil (As of Dec. 2025)


SYMQY SymBio Pharmaceuticals Ltd SYMQY
35 GF Score
Price $0.56
GF Value $0.48
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Total Liabilities?

SymBio Pharmaceuticals SYMQY -12.42% 35 Total Liabilities is $16.65 Mil as of Dec. 2025. GuruFocus rates SYMQY with a GF Score™ of 35/100 and a GF Value™ of $0.48. The stock has 6 warning signs investors should review.

SymBio Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was $16.65 Mil.

SymBio Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2025 ($12.29 Mil) to Sep. 2025 ($19.80 Mil) but then declined from Sep. 2025 ($19.80 Mil) to Dec. 2025 ($16.65 Mil).

SymBio Pharmaceuticals's annual Total Liabilities declined from Dec. 2023 ($6.67 Mil) to Dec. 2024 ($5.01 Mil) but then increased from Dec. 2024 ($5.01 Mil) to Dec. 2025 ($16.65 Mil).

SymBio Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Total Liabilities Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.00 14.29 6.67 5.01 16.65

SymBio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.52 12.29 19.80 16.65 17.11
SYMQY
35GF Score
SymBio Pharmaceuticals Ltd SYMQY
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SymBio Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.276+(8.338+5.8286708792821E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.031+0)
=16.65

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=24.804-8.159
=16.65

SymBio Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.276+(8.338+5.8286708792821E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.031+0)
=16.65

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=24.804-8.159
=16.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $16.65 Mil mean?
SymBio Pharmaceuticals (SYMQY) has a Total Liabilities of $16.65 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Total Liabilities too high?
SymBio Pharmaceuticals' current Total Liabilities is $16.65 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Total Liabilities compare to ZTS and UTHR?
SymBio Pharmaceuticals' Total Liabilities of $16.65 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Total Liabilities is $16.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current Total Liabilities of $16.65 Mil. The stock's GF Value™ is $0.48, compared to a current price of $0.56 — trading 16.2% above its estimated fair value. The current Total Liabilities is $16.65 Mil. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current Total Liabilities is $16.65 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of $0.56 is trading 16.2% above its estimated GF Value™ of $0.48.

Key valuation signals for SYMQY:

  • Total Liabilities: $16.65 Mil
  • GF Value™: $0.48 vs. price of $0.56 (16.2% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Other Exchanges 4582:Japan
Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score

Get the complete analysis for SYMQY

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.48
GF Value